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Abstract
Background: Hepatocellular carcinoma (HCC) is one of the most frequent malignant neoplasms in the world.
Genetic polymorphism has been reported to be a factor increasing the risk of HCC. Phase II enzymes such as
glutathione s-transferases (GSTP1, GSTA1) play important roles in protecting cells against damage induced by
carcinogens. The aim of this study was to estimate the relationship of the GSTP1 and GSTA1 gene polymorphisms
to HCC risk and clinico-pathological status.
Methods: Polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) was used to measure
GSTP1 (A®G) and GSTA1 (C®T) gene polymorphisms in 386 healthy controls and 177 patients with HCC.
Results: Neither gene polymorphism was associated with the clinico-pathological status of HCC and serum
expression of liver-related clinico-pathological markers. No association between the GSTA1 gene polymorphism and
HCC susceptibility was found. However, in the younger group, aged ≤ 57 years, individuals with AG or GG alleles
of GSTP1 had a 2.18-fold (95%CI = 1.09-4.36; p = 0.02) and 5.64-fold (95%CI = 1.02-31.18; p = 0.04) risk, respectively,
of developing HCC compared to individuals with AA alleles, after adjusting for other confounders.
Conclusion: AG and GG alleles of GSTP1 gene polymorphisms may be considered as factors increasing the
susceptibility to and risk of HCC in Taiwanese aged ≤ 57 years.
Background
Hepatocellular carcinoma (HCC) is one of the common
causes of cancer-related death worldwide [1,2], and is
the second leading cause of cancer death in Taiwan [3].
Phase II enzymes such as glutathione s-transferases
(GSTP1, GSTA1) have been suggested to play an impor-
tant role in protecting cells against damage induced by
carcinogens, through regulation of the conjugation of a
wide range of xenobiotics for excretion of hydrophilic
metabolites [4-6]. The isoenzymes of glutathione trans-
ferases, GSTP1 [7-10] and GSTA1 [7,8,11,12], were
found in several mammalian species [7,8] and nontu-
morous liver tissues [9-12]. Significantly increased
expression of GSTP was demonstrated in early hepato-
carcinogenesis [12] and HCC specimens [13], compared
to their adjacent normal tissues or liver cirrhosis tissues.
Loss of GSTP1 has been suggested to increase the risk
of DNA damage and mutation [14,15]. An aberrant
hypermethylation of GSTP1 promoter [9,10,16] and a
subsequently induced lack of GSTP1 mRNA or protein
expression were demonstrated in liver cancer cell lines
[16], and in more than 77.8% of HBV-associated HCC
tissues [9], respectively. Moreover, up-expression of
GSTA was suggested to protect liver cells against oxida-
tive stress [17,18] via an extracellular signal-regulated
kinases (ERKs) and p38 kinase (p38K)-related pathway
[ 1 8 ] ,a sw e l la st h r o u g ht h ei n h i b i t i o no fH 2O2-induced
apoptosis to inhibit reactive oxygen species (ROS)-
induced lipid peroxidation [17].
It was suggested that inactivated or down-regulated
GSTP1 [4,5,9,14,15,19-22] and GSTA1 [23] genes could
increase genomic damage when individuals were
exposed to carcinogens. The GSTP1 gene, encoding glu-
tathione S-transferase-pi and located on chromosome
11q13, was found with a single nucleotide substitution
(A®G) at position 313, which resulted in replacing
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any medium, provided the original work is properly cited.isoleucine (Ile) with valine (Val), substantially reduced
GSTP1 enzyme activity [24,25], and induced slightly
higher adduct levels in liver tissues [26]. Moreover, a
wild genotype C at -69 in the promoter region of the
human GSTA1 gene, designated as GSTA1* A, was sub-
stituted for T, designated as GSTA1*B, which resulted
in decreasing GSTA1 enzyme expression or activity
[11,27,28]. We therefore hypothesized that the phase II
glutathione S-transferase (GST) genes, GSTP1 and
GSTA1, were sensitive marker enzymes for preneoplas-
tic and neoplastic liver cells, and genetic polymorphisms
of these two enzymes could facilitate the susceptibility
to and clinico-pathological development of HCC among
Taiwanese, because more than 67% of male HCC patient
and 55.2% of female HCC patient in Taiwan is related to
hepatitis B virus (HBV) infection and HCV hepatitis C
virus (HCV) infection, respectively [29], which are con-
sidered to be the important risk factors of HCC
[26,30,31]; genetic polymorphisms of GSTP1 and
GSTA1 could decrease the function of detoxification
[11,24,25,27,28] when individuals are exposed to those
risk factors. However, the roles of GSTP1 and GSTA1
gene polymorphisms in the susceptibility to HCC
among Taiwanese have not been fully clarified. The pur-
pose of this study was to investigate the influence of sin-
g l en u c l e o t i d ep o l y m o r p h i s m s( S N P s )o ft h ep h a s eI I
GSTs, GSTP1 and GSTA1, on the susceptibility to and
clinico-pathological development of HCC among
Taiwanese.
Methods
Subjects and specimen collection
This was a hospital-based case-control study. A total of
177 patients with HCC diagnosed at Chung Shan Uni-
versity Hospital, Taichung, or Changhua Christian
Hospital, Changhua, Taiwan, were recruited as a case
group between April 2006 and August 2009. The diag-
noses of HCC were according to the characteristic cri-
teria of the national guidelines for HCC [32], and
included liver injury diagnosed by either histology or
cytology irrespective of a-fetoprotein (AFP) titer, in
which imaging data showed a n yo n eo ft h ef o l l o w i n g
three cases: 1) one or more liver masses more than or
equal to 2 cm in diameter via both computed tomogra-
phy (CT) and magnetic resonance imaging (MRI); 2)
one imaging data with early enhancement and a level
of AFP more than or equal to 400 ng/mL; and 3) one
imaging data with early arterial phase contrast
enhancement plus early venous phase contrast washout
regardless of AFP level. A total of 386 healthy controls
were selected from those who visited the Department
of Family Medicine, Chung Shan Medical University
Hospital, Taiwan for health examination, based on not
having a risk related to hepatocellular carcinoma and
matched on demographic data of race, ethnic group,
gender, and residential area. The whole blood speci-
mens collected from the healthy controls and HCC
patients were placed in tubes containing EDTA and
immediately centrifuged and stored at -80°C. Asso-
ciated clinico-pathological characteristics, such as
HBsAg, anti-HCV, liver cirrhosis history, Child-Pugh
grade, AFP, aspartate aminotransferase (AST), alanine
aminotransferase (ALT), and stage of HCC, were veri-
fied by chart review. This study was performed with
t h ea p p r o v a lo ft h eC h u n gS h a nU n i v e r s i t yH o s p i t a l
Institutional Review Board, and written informed con-
sent was obtained from each individual.
Genomic DNA extraction
Venous blood obtained from each subject was drawn
into Vacutainer tubes containing EDTA and stored at
4°C. Genomic DNA was extracted using a commercial
kit for extracting blood DNA (Qiagen, Valencia, USA),
according to the manufacture’s instructions. DNA was
dissolved in TE buffer [10 mM Tris (PH 7.8), 1 mM
EDTA] and then quantitated by a measurement of
OD260. The final preparation was stored at -20°C and
used as a template for polymerase chain reaction (PCR).
Polymerase chain reaction-restriction fragment length
polymorphism (PCR-RFLP)
The GSTP1 and GSTA1 gene variations test and the
primers were modified [33]. The gene detections were
amplified by PCR. Briefly, PCR was performed in a 10 μl
reaction containing 100 ng DNA template, 1.0 μl of 10×
PCR buffer (Invitrogen, Carslbad, CA, USA), 0.25 U of
Taq DNA polymerase (Invitrogen, Carslbad, CA, USA),
0.2 mM dNTPs (Promega, Madison, WI, USA), and 200
nM of each primer (MDBio Inc. Taipei, Taiwan). The
PCR cycling started at 94°C for 5 min followed by 35
cycles of 94°C for 1 min, 60°C for 1 min and 72°C for
2 min, with a final step at 72°C for 20 min to allow a
complete extension of all PCR fragments. PCR products
of the GSTP1 gene polymorphism were subjected to
enzymatic digestion by incubation with BsmA1 for 4 hr
at 37°C and then electrophoresis in 2% agarose gels.
Wild type homozygous alleles (I/I) yielded 329- and
104-bp products, the heterozygous alleles (I/V) yielded
329-, 222-, 107- and 104-bp products, while the mutated
type homozygous alleles (V/V) yielded a 222-, 107- and
104-bp products. PCR products of the GSTA1 gene
polymorphism were subjected to enzymatic digestion by
incubation with HinfI for 4 hr at 37°C and then electro-
phoresis in 2% agarose gels. Wild type homozygous
alleles (A/A) yielded 525- and 254-bp products, the het-
erozygous alleles (A/B) yielded 525-, 254- and 197-bp
products, while the mutated type homozygous alleles
(B/B) yielded 525- and 197-bp products.
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Based on the hypothesis and our preliminary study, the
frequencies of at least one mutated allele of GSTP1 and
GSTA1 were 29.5% (114/386) and 21.2% (82/386),
respectively. Assuming a 95% confidence interval, a
p value of 0.05, a ratio of cases to healthy controls of
1:2, and at least 90% power to detect a 2.0-fold risk in
gene variances of GSTP1 and GSTA1, the sample sizes
were 150 and 175 case samples for gene polymorphisms
of GSTP1 and GSTA1, respectively.
Statistical analysis
The distributions of demographic characteristics and
genotype frequencies between the cases and controls
and the clinico-pathological features in different geno-
t y p e sw e r ea n a l y z e db yF i s h e r ’s exact test, since the
small sample size was present in some categories of
variables. The odds ratios (ORs) with their 95% confi-
dence intervals (CIs) of the association between geno-
type frequencies and HCC were estimated by multiple
logistic regression models, after controlling for other
covariates, including age, gender and genotypes for each
estimated variable. A non-parametric method was used
because of the non-normal distribution of some esti-
mated variables. The Mann-Whitney U test was used
between two groups, and a Kruskal-Wallis test was used
among three groups. Hardy-Weinberg equilibrium was
assessed using a goodness-of-fit c
2 test for bi-allelic
markers. A p value of less than 0.05 was considered sig-
nificant. The data were analyzed on SAS statistical soft-
ware (Version 9.1, 2005; SAS Institute Inc., Cary, NC).
Results
The frequency distributions of GSTP1 and GSTA1 gene
polymorphisms were studied in 177 HCC patients
and compared to 386 healthy controls. Both gene fre-
quencies were in Hardy-Weinberg equilibrium (GSTP1:
p > 0.05, c
2 value: 0.48; GSTA1: p > 0.05, c
2 value: 0.17,
respectively) in our recruited healthy control group.
The demographic characteristics and the two gene
polymorphism distributions in the HCC patients and
healthy controls are shown in Table 1. Except for age
(p < 0.0001), there was a non-significant difference in
distribution of gender, race, ethnic group, residential
area, and genetic polymorphisms between the HCC
patients and healthy controls, even when we further
classified the individuals with at least one mutated allele
as one subgroup and regarded the individuals with
homozygous wild type alleles as another subgroup to
estimate the adjusted odds ratios (AORs) with their 95%
CIs, or combined different genetic distributions for esti-
mating the interaction effect between the GSTP1 and
GSTA1 gene polymorphisms on the susceptibility to
HCC (Table 1).
Furthermore, we calculated the AOR and their 95%
CIs based on the classification of different age and gen-
der distributions to evaluate the gender- and age-related
genetic polymorphism effect on the susceptibility to
HCC. Since the mean (±SE) and median age of our 563
recruited subjects was 57.36 ± 0.62 and 57.0 years,
respectively, we classified the individuals aged ≤ 57 years
as one subgroup and those aged > 57 years as another
subgroup. In the younger group, aged ≤ 57 years, indivi-
duals with AG or GG alleles of GSTP1 had a 2.18-fold
risk (95% CI: 1.09-4.36, p = 0.02) and 5.64-fold risk
(95% CI: 1.02-31.18, p = 0.04), respectively, of develop-
ing HCC compared to individuals with AA alleles, after
adjustment for other confounders, but no association
was found in the older group, aged > 57 years (Table 2).
No association between the GSTP1 gene polymorphism
and HCC susceptibility was found when we further esti-
mated the relationship based on gender grouping. In
addition, there was no significant relationship between
the GSTA1 gene polymorphism and HCC susceptibility
when we estimated it based on different age (Table 2)
and gender (Table 3) distributions.
To exclude potential selection biases in estimating the
genetic effect on HCC risk, the AOR and 95% CIs of
genotypic frequencies and environmental risk factors,
such as alcohol, tobacco consumption, detection of
hepatitis B surface antigen (HBsAg) and antibody for
HCV (anti-HCV), and history of liver cirrhosis of HCC
patients were estimated. There was a non-significant dif-
ference in distribution between those risk factors and
genetic distributions in our recruited HCC patients. The
AORs with their 95% CIs of GSTP1 and GSTA1 gene
polymorphisms on the clinico-pathological characteris-
tics, such as clinical stage, tumor size, lymph node
metastasis, distant metastasis, and Child-Pugh grade in
HCC patients were also estimated. We found no asso-
ciation between those estimated clinico-pathological
characteristics and gene polymorphisms of GSTP1 and
GSTA1. Furthermore, we estimated the relationship
between genotypic frequencies and expression levels of
clinical pathological markers, such as AFP, AST, and
ALT, as well as the ratio of AST to ALT in HCC
patients. Similarly, non-significant associations between
genetic polymorphisms of GSTP1 and GSTA1 and clin-
ico-pathological markers were found (data not shown).
Discussion
To the best of our knowledge, this is the first study to
provide novel information of GSTP1 and GSTA1
genetic polymorphism effects on HCC risk in
Taiwanese.
In this study, based on a 95% CI and p value of 0.05,
the ratio of cases to healthy controls was 1:2, our sample
s i z eh a da tl e a s t9 0 %p o w e rt od e t e c ta2 . 0 - f o l dr i s ki n
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found that the allelic frequencies of GSTP1 and GSTA1
were not significantly associated with HCC. McGlynn et
al. [34] recruited 231 patients with HCC and 256
healthy controls to examine the association between
gene polymorphisms of GSTP1 and GSTA1 and HCC
among Chinese who were considered to have been
exposed to high levels of aflatoxin B1, a hepatotoxic
mycotoxin induced by fungi of the Aspergillus species.
They found no association between these two gene poly-
morphisms and HCC risk, and suggested a non-genetic
basis for aflatoxin B1-related susceptibility to HCC risk.
Also, Munaka et al. [35] found a non-association
between the GSTP1 polymorphism and HCC risk
among Japanese. Ladero et al. [36] collected 184 white
Spanish patients diagnosed with HCC and 248 healthy
controls to estimate the role of the GSTP1 and GSTA1
gene polymorphism on HCC risk; a non-relation
Table 1 Adjusted odds ratio (AOR) and 95% confidence intervals (CIs) of hepatocellular carcinoma associated with
genotypic frequencies and demographic characteristics distributions.
Variable Controls (n = 386) (%) Patients (n = 177) (%) OR (95% CI) p value AOR (95% CI) p value
GSTP1
II 272 (70.5%) 112 (63.3%) 1.00 1.00
IV 107 (27.7%) 58 (32.7%) 1.31 (0.8-1.9) p = 0.16 1.16 (0.7-1.7) p = 0.46
VV 7 (1.8%) 7 (4.0%) 2.42 (0.8-7.0) p = 0.10 2.26 (0.7-7.1) p = 0.16
II 272 (70.5%) 112 (63.3%) 1.00 1.00
IV or VV 114 (29.5%) 65 (36.7%) 1.38 (0.9-2.0) p = 0.09 1.24 (0.8-1.8) p = 0.28
GSTA1
AA 304 (78.8%) 146 (82.5%) 1.00 1.00
AB 78 (20.2%) 30 (16.9%) 0.80 (0.5-1.2) p = 0.34 0.89 (0.5-1.4) p = 0.66
BB 4 (1.0%) 1 (0.6%) 0.52 (0.05-4.7) p = 0.56 0.34 (0.04-3.5) p = 0.38
AA 304 (78.8%) 146 (82.5%) 1.00 1.00
AB or BB 82 (21.2%) 31 (17.5%) 0.78 (0.4-1.2) p = 0.36 0.85 (0.5-1.3) p = 0.52
GST genes
Combination 1 212 (54.9%) 92 (52.0%) 1.00 1.00
Combination 2 152 (39.4%) 75 (42.3%) 1.13 (0.7-1.6) p = 0.51 1.05 (0.7-1.5) p = 0.77
Combination 3 22 (5.7%) 10 (5.7%) 1.04 (0.4-2.4) p = 0.81 1.08 (0.4-2.5) p = 0.84
Age (yrs)
54.37 ± 0.77 63.88 ± 0.81 p < 0.0001
Gender
Male 257 (66.6%) 128 (72.3%) 1.00 1.00
Female 129 (33.4%) 49 (27.7%) 0.76 (0.5-1.1) p = 0.17 1.08 (0.7-1.6) p = 0.72
Residential area Mid-Taiwan Mid-Taiwan
Race Asian Asian
Ethnicity Taiwanese Taiwanese
The odds ratios (ORs) with their 95% CIs were estimated by logistic regression models.
The adjusted odds ratios (AORs) with their 95% CIs were estimated by multiple logistic regression models, after controlling for age, gender and genotypes for
each estimated variable.
Mann-Whitney U test or Fisher’s exact test was used between healthy controls and HCC patients.
Combination 1: Individuals with Ile/Ile of GSTP1 and *A/*A of GSTA.
Combination 2: Individuals with either genotype Ile/Val or Val/Val of GSTP1 or genotype *A/*B or *B/*B of GSTA1.
Combination 3: Individuals with genotype Ile/Val or Val/Val of GSTP1 and genotype *A/*B or *B/*B of GSTA1.
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genotypic frequencies in different age groups.
Variable Controls n (%) Patients n (%) OR (95% CI) p value AOR (95% CI) p value
Age > 57 years old
GSTP1 n = 149 n = 129
II 93 (62.4%) 85 (65.9%) 1.00 1.00
IV 52 (34.9%) 40 (31.0%) 0.84 (0.5-1.3) p = 0.50 0.88 (0.5-1.4) p = 0.63
VV 4 (2.7%) 4 (3.1%) 1.09 (0.2-4.5) p = 0.90 1.06 (0.2-4.6) p = 0.93
GSTA1 n = 149 n = 129
AA 122 (81.9%) 106 (82.2%) 1.00 1.00
AB 24 (16.1%) 22 (17.1%) 1.05 (0.5-1.9) p = 0.86 1.05 (0.5-2.0) p = 0.87
BB 3 (2.0%) 1 (0.8%) 0.38 (0.03-3.7) p = 0.40 0.47 (0.04-4.68) p = 0.52
Age ≤ 57 years old
GSTP1 n = 237 n = 48
II 179 (75.5%) 27 (56.3%) 1.00 1.00
IV 55 (23.2%) 18 (37.5%) 2.17 (1.1-4.2) p = 0.02 2.18 (1.1-4.3) p = 0.02
VV 3 (1.3%) 3 (6.2%) 6.63 (1.2-34.5) p = 0.02 5.64 (1.1-31.8) p = 0.04
GSTA1 n = 237 n = 48
AA 182 (76.8%) 40 (83.3%) 1.00 1.00
AB 54 (22.8%) 8 (16.7%) 0.67 (0.2-1.5) p = 0.34 0.62 (0.2-1.4) p = 0.28
BB 1 (0.4%) 0 (0%) - p = 0.99 - p = 0.99
The odds ratios (ORs) with their 95% CIs were estimated by logistic regression models.
The adjusted odds ratios (AORs) with their 95% CIs were estimated by multiple logistic regression models, after controlling for gender and genotypes for each
estimated variable.
Table 3 Adjusted odds ratio (AOR) and 95% confidence intervals (CIs) of hepatocellular carcinoma associated with
genotypic frequencies in different gender groups.
Variable Controls n (%) Patients n (%) OR (95% CI) p value AOR (95% CI) p value
Male
GSTP1 n = 257 n = 128
II 179 (69.7%) 76 (59.4%) 1.00 1.00
IV 72 (28.0%) 47 (36.7%) 1.53 (0.9-2.4) p = 0.06 1.41 (0.8-2.2) p = 0.14
VV 6 (2.3%) 5 (3.9%) 1.96 (0.5-6.6) p = 0.27 1.95 (0.5-6.7) p = 0.29
GSTA1 n = 257 n = 128
AA 200 (77.8%) 107 (83.6%) 1.00 1.00
AB 53 (20.6%) 20 (15.6%) 0.70 (0.4-1.2) p = 0.22 0.76 (0.4-1.3) p = 0.35
BB 4 (1.6%) 1 (0.8%) 0.46 (0.05-4.2) p = 0.49 0.45 (0.04-4.2) p = 0.49
Female
GSTP1 n = 129 n = 49
II 93 (72.1%) 36 (73.5%) 1.00 1.00
IV 35 (27.1%) 11 (22.4%) 0.81 (0.3-1.7) p = 0.60 0.57 (0.2-1.5) p = 0.28
VV 1 (0.8%) 2 (4.1%) 5.16 (0.4-58.7) p = 0.18 3.67 (0.1-107.8) p = 0.45
GSTA1 n = 129 n = 49
AA 104 (80.6%) 39 (79.6%) 1.00 1.00
AB 25 (19.4%) 10 (20.4%) 1.06 (0.4-2.4) p = 0.87 1.70 (0.5-5.3) p = 0.36
BB 0 (0%) 0 (0%) - -
The odds ratios (ORs) with their 95% CIs were estimated by logistic regression models.
The adjusted odds ratios (AORs) with their 95% CIs were estimated by multiple logistic regression models, after controlling for age and genotypes for each
estimated variable.
Chen et al. BMC Medical Genetics 2010, 11:46
http://www.biomedcentral.com/1471-2350/11/46
Page 5 of 8between the genetic polymorphism and HCC was found.
Although these three studies estimated the relationship
between GSTP1 and GSTA1 gene polymorphisms and
HCC risk based on different populations with allelic fre-
quencies and environmental exposure different from our
recruited population, their results were in agreement
with ours. There are other possible explanations for why
an individual is not susceptible to HCC, aside from the
single nucleotide polymorphisms of GSTP1 and GSTA1,
such as linked genes.
However, in the younger group, age ≤ 57 years old,
individuals with AG or GG alleles of GSTP1 had a
2.18-fold risk (95% CI: 1.09-4.36, p = 0.02) and 5.64-
fold risk (95% CI: 1.02-31.18, p = 0.04) of developing
HCC compared to individuals with AA alleles, after
adjustment for other confounders, but no association
was found in the older group, aged > 57 years.
Increased GSTP gene expression was found during early
hepatocarcinogenesis by acetylation of histones H3 and
H4 and interaction with the specific transcription factor
i nt h ep r o m o t e rr e g i o n so ft h eG S T Pg e n e[ 1 2 ] .M o r e -
over, a marked expression of GSTP was found in HCC
specimens of HCC patients [13]. It was supposed that
normal or increased GSTP1 protein levels or activities
contributed to defend normal hepatocytes against a
variety of potentially promutagenic stresses [4-6,14,20],
assist detoxification, and inhibit mutagenesis [4-6,14,20].
In the present study, the age-related effect of GSTP1
AG and GG alleles on HCC susceptibility in the
younger group, aged ≤ 57 years, but not in the older
group, aged > 57 years, may have resulted from: 1) The
younger group, aged ≤ 57 years, was more likely
exposed to HCC-related risk factors [26,29-31]. The G
allele of GSTP1 induced the replacement of isoleucine
(Ile) with valine (Val) and substantially reduced GSTP1
enzyme activity [24,25], increased the risk of DNA
mutation [14,15], and resulted in poor elimination of
hydrophilic metabolites [4-6], consequently increasing
the susceptibility to HCC when individuals are exposed
to carcinogens [9]; 2) Aging was an important risk fac-
tor for HCC development [38-40]. The aging effect may
have contributed to the non-significant effect of the
GSTP1 genetic variant on HCC risk in our older group,
because aging-related GSTP1 hyper-methylation was
found in normal human tissues [38,39]. This induced
the lack of GSTP1 expression [9,16] and may have con-
tributed to carcinogenic development [38,39] and abated
the genetic polymorphism effect in the older group.
Moreover, different mechanisms contributing to carci-
nogenesis development were demonstrated in different
age groups among other diseases [40,41]. Tremblay et
al. [41] recruited 42 young patients (age: 21-40 years)
with oral squamous cell carcinomas (OSCCs) and 62
older (age: 60-95 years) OSCCs patients to detect
GSTP1 expression in tumor tissues and found a signifi-
cantly decreased expression of GSTP1 in the tumors of
young patients compared to their nondysplastic mucosa,
but an increased expression of GSTP1 in tumors of
older patients compared with their nondysplastic
mucosa [41]. Although those hypotheses need further
demonstration in HCC development, we provided a
novel finding, that the GSTP1 gene polymorphism
increased age-related susceptibility to HCC, particularly
for subjects aged ≤ 57 years.
Increased serum levels of AST and ALT are highly
correlated with increased expression of GSTA1 [42-44]
and GSTP1 [45]. In this study, we estimated the roles of
these two gene polymorphisms on the clinical status,
such as clinical stage, tumor size, lymph node metasta-
sis, distant metastasis, Child-Pugh grade, and the serum
expression levels of liver-related clinical pathological
markers, such as alpha-fetoprotein, AST, and ALT, as
well as the ratio of AST to ALT in HCC patients.
A lack of association between the gene polymorphism
and those estimated factors was found in both GSTP1
and GSTA1 genes. We propose that the age-related
GSTP1 gene polymorphism contributes to the suscept-
ibility to HCC, and not through the alteration of the
expression of those clinical pathological markers.
One of the limitations of our study is that we did not
obtain information on risk factors, such as alcohol,
tobacco consumption, and other hepatocarcinogenesis-
related factors [30] in our recruited healthy control
group, because it was difficult to request healthy indivi-
duals to provide that information or to collect that data
during their health examination. This limitation may
impede the adjustment of the confounding variables.
However, in order to exclude a potential selection bias
in estimating the genetic effect on HCC risk, the AOR
and 95% CIs of genotypic frequencies and environmen-
tal risk factors, such as alcohol, tobacco consumption,
detection of hepatitis B surface antigen (HBsAg) and
antibody for HCV (anti-HCV), and the history of liver
cirrhosis of HCC patients, were estimated, and there
was a non-significant difference in distribution between
those risk factors and the genetic distributions in our
recruited HCC patients. Moreover, other demographic
characteristics such as age, gender, race, and, residential
area were adjusted for estimation of gene polymorphism
effect on HCC between the healthy controls and HCC
patients. We consider that this limitation is unlikely to
bound the estimation of genetic effect on HCC risk in
this study.
Conclusion
AG and GG alleles of GSTP1 gene polymorphisms may
be considered as factors increasing the susceptibility to
the risk of HCC in Taiwanese subjects ages ≤ 57 years.
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